USMEF Statement on Colombia Fully Reopening to U.S. Beef

Sep 26, 2024

With the Colombian government recently lifting its ban on U.S. beef originating from states in which H5N1 was detected in dairy cows, the Export Library for Colombia has been updated to reflect restored access for beef from 14 states.

U.S. Meat Export Federation (USMEF) President and CEO Dan Halstrom issued the following statement:

On behalf of USMEF’s membership, I want to thank the U.S. government, and especially the teams at the USDA Animal and Plant Health Inspection Service (APHIS), Foreign Agricultural Service (FAS) and Food Safety and Inspection Service (FSIS) involved in the effort to restore full access for U.S. beef shipments to Colombia. The USDA staff posted in Bogota, in particular, worked tirelessly to get these restrictions lifted. We are also grateful to Colombian importers and customers who remained loyal to U.S. beef during this difficult time and who voiced their concerns to the Colombian government about the interruption in trade.

It is also important to note that effective USDA engagement with other trading partners helped prevent similar trade barriers from affecting additional export markets.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.